Stemcyte International Ltd.

As of June 30, 2026, Stemcyte International Ltd. carries a market capitalization of 3.96B, placing it among publicly traded companies globally. Its enterprise value stands at 1.61B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Stemcyte International Ltd. has 215.87M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 10.11, and the price-to-book ratio stands at 1.93.

These figures are as of June 30, 2026. The EV/Sales ratio of 4.51 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.61B versus a market cap of 3.96B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Stemcyte International Ltd. maintains a current ratio of 11.60, meaning it holds 11.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 8.83, indicating elevated leverage, while an interest coverage ratio of -14.14 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Stemcyte International Ltd. posted a negative return on equity (ROE) of -9.57, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -5.57, reflecting losses generated across the asset base. The company generates approximately 3.02M in revenue per employee across its workforce of 117.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.64 indicates how many times Stemcyte International Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Stemcyte International Ltd. recorded 3.63M in income tax expense. The company reported a pretax loss of -175.61M and -179.24M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

These figures are as of the close on October 22, 2026.

Over the twelve months ended June 30, 2026, Stemcyte International Ltd. generated 356.05M in revenue and converted that into -179.24M in net income, yielding earnings per share of -0.91. EBITDA reached -179.74M, while operating income came in at -238.69M.

As of June 30, 2026, Stemcyte International Ltd. holds 2.54B in cash and equivalents against 181.02M in total debt, resulting in a net debt position of -2.14B. Total book value stands at 2.05B, with working capital of 2.78B providing operational flexibility.

Stemcyte International Ltd. produced -53.45M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.43M in capital expenditures, free cash flow totaled -54.89M - equivalent to -0.28 per share.

Over the twelve months ended June 30, 2026, Stemcyte International Ltd. posted a gross margin of 30.15, reflecting its pricing power and cost economics. The operating margin of -67.04 and net profit margin of -50.34 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -1.53: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -10.56, meaning Stemcyte International Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Stemcyte International Ltd. has an Altman Z-Score of 1.92, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.